

# Novocastra™ Liquid Mouse Monoclonal Antibody VEGFR-3

## Product Code: NCL-L-VEGFR-3

<b>Intended Use</b>	FOR RESEARCH USE ONLY.
<b>Specificity</b>	Human vascular endothelial growth factor receptor-3 (VEGFR-3).
<b>Clone</b>	KLT9
<b>Ig Class</b>	IgG2b kappa
<b>Antigen Used for Immunizations</b>	A 227 amino acid region of the external domain of the human VEGFR-3 molecule.
<b>Hybridoma Partner</b>	Mouse myeloma (p3-NS1-Ag4-1).
<b>Preparation</b>	Liquid tissue culture supernatant containing 15 mM sodium azide. Volume as indicated on vial label.
<b>Effective on Frozen Tissue</b>	Not evaluated.
<b>Effective on Paraffin Wax Embedded Tissue</b>	Yes
<b>Recommendations on Use</b>	Immunohistochemistry: Typical working dilution 1:50–1:100. 60 minutes primary antibody incubation at 25 °C. Standard ABC technique. Western Blotting: Not recommended.
<b>Positive Controls</b>	Immunohistochemistry: Placenta.
<b>Staining Pattern</b>	Cytoplasmic.
<b>Storage and Stability</b>	Store liquid antibody at 4 °C. Under these conditions, there is no significant loss in product performance up to the expiry date indicated on the vial label. Prepare working dilutions on the day of use.
<b>General Overview</b>	VEGFR-3 (FLT4) is a receptor tyrosine kinase similar in structure to VEGFR-1 and VEGFR-2 but does not bind VEGF. However, the two known ligands VEGF-C and VEGF-D have a high degree of homology to VEGF. VEGFR-3 is found in many tissues including lung, intestine, brain, and placenta (syncytiotrophoblasts). Throughout embryogenesis VEGFR-3 mRNA is expressed in most endothelial cells, whilst being restricted to lymphatic vessels later in development. It appears to play an important role in the normal development of blood and lymphatic vessels.
<b>General References</b>	Witmer A N, Dai J, Weich H A, et al.. <i>The Journal of Histochemistry and Cytochemistry</i> . 50 (6): 767–777 (2002). Helske S, Vuorela P, Carpén O, et al.. <i>Molecular Human Reproduction</i> . 7 (2): 205–210 (2001). Niki T, Iba S, Yamada T, et al.. <i>Journal of Pathology</i> . 193: 450–457 (2001). Ravindranath N, Wion D, Brachet P, et al.. <i>Journal of Andrology</i> . 22 (3): 432–443 (2001). Yonemura Y, Fushida S, Bando E, et al.. <i>European Journal of Cancer</i> . 37 (7): 918–923 (2001). Valtola R, Salven P, Heikkilä P, et al.. <i>American Journal of Pathology</i> . 154 (5): 1381–1390 (1999). Jussila L, Valtola R, Partanen T A, et al.. <i>Cancer Research</i> . 58: 1599–1604 (1998). Lymboussaki A, Partanen T A, Olofsson B, et al.. <i>American Journal of Pathology</i> . 153 (2): 395–403 (1998). Galland F, Karamysheva A, Pebusque M, et al.. <i>Oncogene</i> . 8: 1233–1240 (1993).

